Daxor Corporation

NasdaqCM:DXR Stock Report

Market Cap: US$61.4m

Daxor Future Growth

Future criteria checks 2/6

Daxor's earnings are forecast to decline at 133.1% per annum while its annual revenue is expected to grow at 95.3% per year. EPS is expected to decline by 134.7% per annum.

Key information

-133.1%

Earnings growth rate

-134.74%

EPS growth rate

Medical Equipment earnings growth16.4%
Revenue growth rate95.3%
Future return on equityn/a
Analyst coverage

Low

Last updated26 May 2026

Recent future growth updates

No updates

Recent updates

Seeking Alpha Aug 25

Daxor reports Q2 results

Daxor press release (NASDAQ:DXR): Q2 The increase in revenue of 92.6 percent in the Company’s operating division represents strong strides in the commercialization of its BVA-100. As of June 30, 2022 the company held net assets of $19,615,712 or $4.85 per share, a 35.3 percent increase versus the same period in the prior year.
Seeking Alpha Jul 21

Daxor partners with Medaxiom to advance awareness of blood volume diagnostic

Daxor (NASDAQ:DXR) said it had partnered with Medaxiom to advance awareness and adoption of Daxor’s blood volume diagnostic. "With heart failure diagnosis continuing to increase, access to accurate blood volume testing will transform the way care decisions are made,” said Joe Sasson, MedAxiom’s EVP of Ventures.
Analysis Article Mar 08

Daxor's (NASDAQ:DXR) Earnings Aren't As Good As They Appear

We didn't see Daxor Corporation's ( NASDAQ:DXR ) stock surge when it reported robust earnings recently. We decided to...
Analysis Article Feb 27

A Look At The Fair Value Of Daxor Corporation (NYSEMKT:DXR)

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Daxor Corporation...

Earnings and Revenue Growth Forecasts

NasdaqCM:DXR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027210N/AN/A1
12/31/202612-1N/AN/A1
12/31/20250911N/A
9/30/20250511N/A
6/30/20250211N/A
3/31/20250111N/A
12/31/20240100N/A
9/30/202401-1-1N/A
6/30/202402-2-2N/A
3/31/202401-3-3N/A
12/31/202300-4-4N/A
9/30/202302-3-3N/A
6/30/202304-3-3N/A
3/31/202305-2-2N/A
12/31/202205-1-1N/A
9/30/202205-1-1N/A
6/30/202204-2-2N/A
3/31/202205-2-2N/A
12/31/202105-3-3N/A
9/30/202103-3-3N/A
6/30/202100-2-2N/A
3/31/20210-1-2-2N/A
12/31/20200-2-2-2N/A
9/30/20200-300N/A
6/30/20200-422N/A
3/31/20200-222N/A
12/31/20190033N/A
9/30/201900N/A1N/A
6/30/201900N/A-1N/A
3/31/201900N/A-1N/A
12/31/20180-1N/A-1N/A
9/30/20180-1N/A-1N/A
6/30/20181-1N/A0N/A
3/31/20181-1N/A-1N/A
12/31/20171-1N/A-1N/A
9/30/20171-1N/A2N/A
6/30/20171-1N/A6N/A
3/31/201710N/A4N/A
12/31/201611N/A2N/A
9/30/20161-1N/A0N/A
6/30/20161-3N/A-1N/A
3/31/20161-6N/A9N/A
12/31/20151-9N/A19N/A
9/30/20151-7N/A14N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: DXR's earnings are forecast to decline over the next 3 years (-133.1% per year).

Earnings vs Market: DXR's earnings are forecast to decline over the next 3 years (-133.1% per year).

High Growth Earnings: DXR's earnings are forecast to decline over the next 3 years.

Revenue vs Market: DXR's revenue (95.3% per year) is forecast to grow faster than the US market (12.7% per year).

High Growth Revenue: DXR's revenue (95.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DXR's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/07 22:41
End of Day Share Price 2026/07/07 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Daxor Corporation is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Frank TakkinenLake Street Capital Markets, LLC
Scott HenryRoth Capital Partners